AU680824B2 - Suppression of T-cell proliferation using peptide fragments of myelin basic protein - Google Patents

Suppression of T-cell proliferation using peptide fragments of myelin basic protein Download PDF

Info

Publication number
AU680824B2
AU680824B2 AU42824/93A AU4282493A AU680824B2 AU 680824 B2 AU680824 B2 AU 680824B2 AU 42824/93 A AU42824/93 A AU 42824/93A AU 4282493 A AU4282493 A AU 4282493A AU 680824 B2 AU680824 B2 AU 680824B2
Authority
AU
Australia
Prior art keywords
amino acid
mbp
cells
acid residues
hmbp
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU42824/93A
Other languages
English (en)
Other versions
AU4282493A (en
Inventor
Ahmad Al-Sabbagh
David A. Hafler
Ariel Miller
Howard L. Weiner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Autoimmune Inc
Original Assignee
Autoimmune Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Autoimmune Inc filed Critical Autoimmune Inc
Publication of AU4282493A publication Critical patent/AU4282493A/en
Application granted granted Critical
Publication of AU680824B2 publication Critical patent/AU680824B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Rehabilitation Therapy (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU42824/93A 1992-04-09 1993-04-09 Suppression of T-cell proliferation using peptide fragments of myelin basic protein Ceased AU680824B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US86531892A 1992-04-09 1992-04-09
US865318 1992-04-09
PCT/US1993/003369 WO1993021222A1 (en) 1992-04-09 1993-04-09 Suppression of t-cell proliferation using peptide fragments of myelin basic protein

Publications (2)

Publication Number Publication Date
AU4282493A AU4282493A (en) 1993-11-18
AU680824B2 true AU680824B2 (en) 1997-08-14

Family

ID=25345228

Family Applications (1)

Application Number Title Priority Date Filing Date
AU42824/93A Ceased AU680824B2 (en) 1992-04-09 1993-04-09 Suppression of T-cell proliferation using peptide fragments of myelin basic protein

Country Status (15)

Country Link
EP (2) EP0650498B1 (enExample)
JP (1) JP3434510B2 (enExample)
KR (1) KR950700934A (enExample)
AT (2) ATE212358T1 (enExample)
AU (1) AU680824B2 (enExample)
BR (1) BR9306272A (enExample)
CA (1) CA2133749A1 (enExample)
DE (2) DE69331501T2 (enExample)
DK (1) DK0863155T3 (enExample)
ES (1) ES2172044T3 (enExample)
HU (1) HU219306B (enExample)
IL (1) IL105347A0 (enExample)
NO (1) NO317049B1 (enExample)
PT (1) PT863155E (enExample)
WO (1) WO1993021222A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5869054A (en) * 1987-06-24 1999-02-09 Autoimmune Inc. Treatment of multiple sclerosis by oral administration of autoantigens
US5817629A (en) * 1991-10-22 1998-10-06 The Governors Of The University Of Alberta Peptide specificity of anti-myelin basic protein and the administration of myelin basic protein peptides to multiple sclerosis patients
US6252040B1 (en) 1991-10-22 2001-06-26 The Governors Of The University Of Alberta Peptide specificity of anti-myelin basic protein and the administration of myelin basic protein peptides to multiple sclerosis patients
JPH10500109A (ja) * 1994-05-10 1998-01-06 イミユロジク・フアーマシユーチカル・コーポレーシヨン 多発性硬化症のための組成物および治療方法
CZ122697A3 (en) * 1994-10-25 1997-09-17 Immulogic Pharma Corp Preparations and methods of treating disseminated sclerosis
US6379670B1 (en) 1994-11-18 2002-04-30 Neurocrine Biosciences, Inc. Methods for treatment of multiple sclerosis using peptide analogs of human myelin basic protein
US6329499B1 (en) * 1994-11-18 2001-12-11 Neurocrine Biosciences, Inc. Methods for treatment of multiple sclerosis using peptide analogues of human myelin basic protein
AU721898B2 (en) * 1994-11-18 2000-07-20 Board Of Trustees Of The Leland Stanford Junior University Methods for treatment of multiple sclerosis using peptide analogues at position 91 of human myelin basic protein
US6251396B1 (en) 1994-11-18 2001-06-26 Neurocrine Biosciences, Inc. Methods for treatment of multiple sclerosis using peptide analogs of human myelin basic protein
WO1996028470A2 (en) * 1995-03-09 1996-09-19 Neurocrine Biosciences, Inc. Peptide analogues of human myelin basic protein useful in treating multiple sclerosis
US5856446A (en) * 1995-07-07 1999-01-05 Autoimmune Inc. Method of treating rheumatoid arthritis with low dose type II collagen
IL116559A (en) * 1995-11-17 2005-11-20 Yissum Res Dev Co Chimeric protein consisting of a bacterial toxin and a myelin basic protein sequence
US6274136B1 (en) * 1996-05-29 2001-08-14 University Of Southern California Construction and use of genes encoding pathogenic epitopes for treatment of autoimmune disease
CA2494338C (en) * 1997-04-04 2007-07-17 The Governors Of The University Of Alberta Peptide specificity of anti-myelin basic protein and the administration of myelin basic protein peptides to multiple sclerosis patients
US20020072493A1 (en) 1998-05-19 2002-06-13 Yeda Research And Development Co. Ltd. Activated T cells, nervous system-specific antigens and their uses
WO1999060021A2 (en) * 1998-05-19 1999-11-25 Yeda Research And Development Co. Ltd. Use of activated t cells, nervous system-specific antigens for treating disorders of the nevrous system
WO2001089557A2 (en) 2000-05-24 2001-11-29 The United States Of America, As Represented By Secretary Of The Department Of Health & Human Services Methods for preventing strokes by inducing tolerance to e-selectin
JP2007509063A (ja) 2003-10-17 2007-04-12 ベイラー　カレッジ　オブ　メディスン Ｃｄ８＋細胞傷害性ｔ細胞応答を増大させる方法、および多発性硬化症を処置するための方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU695801B2 (en) * 1993-09-22 1998-08-20 Board Of Trustees Of The Leland Stanford Junior University Interaction of T-cell receptors and antigen in autoimmune disease
AU721898B2 (en) * 1994-11-18 2000-07-20 Board Of Trustees Of The Leland Stanford Junior University Methods for treatment of multiple sclerosis using peptide analogues at position 91 of human myelin basic protein

Also Published As

Publication number Publication date
CA2133749A1 (en) 1993-10-28
DE69320967T2 (de) 1999-05-12
KR100295606B1 (enExample) 2001-10-22
WO1993021222A1 (en) 1993-10-28
NO943755D0 (no) 1994-10-06
ATE170874T1 (de) 1998-09-15
BR9306272A (pt) 1998-06-23
EP0650498A1 (en) 1995-05-03
HU9402909D0 (en) 1995-01-30
DE69331501T2 (de) 2002-08-29
DE69331501D1 (de) 2002-03-14
ES2172044T3 (es) 2002-09-16
DE69320967D1 (de) 1998-10-15
IL105347A0 (en) 1993-08-18
NO317049B1 (no) 2004-07-26
AU4282493A (en) 1993-11-18
PT863155E (pt) 2002-07-31
HU219306B (en) 2001-03-28
JPH08500083A (ja) 1996-01-09
DK0863155T3 (da) 2002-05-13
EP0650498A4 (en) 1995-06-21
JP3434510B2 (ja) 2003-08-11
EP0863155B1 (en) 2002-01-23
NO943755L (no) 1994-12-02
KR950700934A (ko) 1995-02-20
HUT69169A (en) 1995-08-28
ATE212358T1 (de) 2002-02-15
EP0650498B1 (en) 1998-09-09
EP0863155A1 (en) 1998-09-09

Similar Documents

Publication Publication Date Title
US5858980A (en) Peptide fragments of myelin basic protein
US8343500B2 (en) Peptide composition
EP0650498B1 (en) Suppression of t-cell proliferation using peptide fragments of myelin basic protein
Martin et al. Immunological aspects of experimental allergic encephalomyelitis and multiple sclerosis
Martin et al. Fine specificity and HLA restriction of myelin basic protein-specific cytotoxic T cell lines from multiple sclerosis patients and healthy individuals.
US9775880B2 (en) Methods of using myelin basis protein peptide compositions
EP0522091B9 (en) Use of a mbp peptide for the preparation of a medicament for the treatment of multiple sclerosis
HUT77047A (hu) Szklerózis multiplex kezelésére szolgáló készítmények és kezelések
AU674494B2 (en) T cell receptor peptides as therapeutics for immune-related disease
US6039947A (en) Peptides derived from immunodominant epitopes of myelin basic protein
Richert Human T-cell recognition of myelin basic protein peptides
HK1142803B (en) Compositions comprising myelin basic protein peptides and medical uses thereof